Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Renal Insufficiency 1Paraproteinemias 1Neoplasms, Plasma Cell 1Neoplasms by Histologic Type 1Neoplasms 1Multiple Myeloma 1Hematologic Diseases 1Blood Protein Disorders 1

Interventions

Dexamethasone 64Cyclophosphamide 40Bortezomib 37Melphalan 24Lenalidomide 23Thalidomide 17pomalidomide 16fludarabine 12daratumumab 11carfilzomib 10Filgrastim 8Doxorubicin 8Busulfan 6Prednisone 5Peripheral Blood Stem Cell Transplantation 5Bendamustine Hydrochloride 5selinexor 4sargramostim 4isatuximab 4fludarabine phosphate 4Surveys and Questionnaires 4Etoposide 4Clarithromycin 4Calcium Dobesilate 4liposomal doxorubicin 3ixazomib 3Radiotherapy 3Neoadjuvant Therapy 3Mycophenolic Acid 3Methylprednisolone 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Multiple Myeloma × Ranitidine × Clear all
NCT05298683 2022-03-28

A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor

Hellenic Society of Hematology

Phase 2 Unknown
108 enrolled
Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Renal Insufficiency, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡